Compare Ascendis Pharma A/S (ASND) vs Tesla, Inc. (TSLA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Tesla, Inc. — how do they compare? Ascendis Pharma A/S trades at $254.01 (market cap $16.67B), while Tesla, Inc. trades at $333.8 (market cap $1.31T). The key difference: Tesla, Inc. is far larger — about 78.6× Ascendis Pharma A/S's market cap, and Ascendis Pharma A/S is trading nearer its 52-week high, Tesla, Inc. nearer its low. Which is the better fit depends on your goals.
| ASND | TSLA | |
|---|---|---|
Market Cap | $16.67B | $1.31T |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $489.88 |
52-Week Low | $189.74 | $298.16 |
Enterprise Value | $17.04B | $1.29T |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Tesla (TSLA) trades at $330.87, up 0.7% today, amid a mixed technical and fundamental backdrop. The stock shows a bearish technical signal with key resistance at $333 and support at $327, while fundamentals reveal high valuation multiples (P/E 306.37) and declining profit margins (net margin 3.67% in 2025). Recent news highlights regulatory approval for self-driving software in Europe and a potential cheaper EV launch, balancing near-term delivery misses with long-term innovation bets.
Tesla's outlook hinges on executing its pivot to AI and autonomy amid slowing auto growth. Investment opportunities lie in market leadership in self-driving technology and energy expansion, but risks include intense EV competition, execution challenges, and rich valuations that demand flawless growth. Wall Street remains divided, with a $393.87 consensus target suggesting upside if catalysts materialize.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Tesla, Inc.
Tesla Inc. designs, manufactures, and sells high-performance electric vehicles and electric vehicle powertrain components. The Company owns its sales and service network and sells electric power train components to other automobile manufacturers. Tesla serves customers worldwide.
Read more on TSLA →
